Antibody Production Services — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Antibody Production Services Ltd. is a well-established, privately-held contract service provider founded in 2002 and based in Cambridge, UK. The company offers a comprehensive suite of antibody development services, utilizing a wide range of host animals and maintaining high-quality certifications. With deep historical roots in the field, including leadership with connections to foundational monoclonal antibody work, APS serves a global clientele from its secure UK facilities, positioning itself as a flexible and experienced partner in the research and diagnostic supply chain.

Antibodies

Technology Platform

Integrated custom antibody generation service platform encompassing antigen design, peptide synthesis, immunization in a wide range of host animals (rabbits, sheep, goats, chickens, mice, alpacas, etc.), hybridoma fusion, assay development, and antibody purification/scale-up/characterization. Includes single-domain antibody (sdAb) development capability.

Opportunities

Growth is driven by sustained demand for custom antibodies in research, diagnostics, and therapeutic development, with particular opportunity in the high-quality, regulated diagnostic reagent sector.

The expanding field of single-domain antibodies represents a forward-looking service niche with therapeutic and diagnostic applications.

Risk Factors

Key risks include regulatory and public relations challenges associated with animal research, intense competition in the global CRO/CDMO space, and potential long-term technological disruption from in vitro display methods.

Dependence on the UK's regulatory environment for animal work is also a factor.

Competitive Landscape

APS competes in a crowded global market of antibody service CROs and CDMOs. It differentiates through its wide host animal selection, strong UK regulatory and quality certifications (ISO, APHA), and deep historical expertise. Competitors range from large international CDMOs to specialized boutique firms and lower-cost providers in Asia.

More companies in Biologics / Biosimilars →More companies in United Kingdom →